AFM
SPRO icon

Anson Funds Management’s Spero Therapeutics SPRO Stock Holding History

Anson Funds Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-421,956
Closed -$987K – 204
2026
Q1 		$987K Sell
421,956
-203,106
-32% -$482K 0.09% 107
2025
Q4 		$1.46M Sell
625,062
-978,507
-61% -$2.27M 0.14% 80
2025
Q3 		$3.01M Sell
1,603,569
-11,900
-0.7% -$26.2K 0.27% 61
2025
Q2 		$4.68M Sell
1,615,469
-2,183,463
-57% -$3.14M 0.67% 30
2025
Q1 		$2.74M Sell
3,798,932
-40,954
-1% -$34.6K 0.5% 45
2024
Q4 		$3.96M Buy
3,839,886
+89,436
+2% +$106K 0.4% 40
2024
Q3 		$5.03M Hold
3,750,450
– – 0.5% 30
2024
Q2 		$4.88M Hold
3,750,450
– – 0.58% 25
2024
Q1 		$6.45M Sell
3,750,450
-547,249
-13% -$858K 0.42% 31
2023
Q4 		$6.32M Buy
4,297,699
+138,127
+3% +$165K 0.78% 29
2023
Q3 		$5.03M Buy
4,159,572
+714,710
+21% +$990K 1.01% 21
2023
Q2 		$5M Buy
3,444,862
+100,000
+3% +$171K 0.83% 24
2023
Q1 		$4.85M Buy
3,344,862
+325,254
+11% +$544K 0.79% 32
2022
Q4 		$5.22M Buy
3,019,608
+1,545,736
+105% +$2.89M 0.86% 29
2022
Q3 		$2.95M Buy
+1,473,872
New +$1.47M 0.35% 65

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Anson Funds Management's SPRO Position: Q2 2026 in Review

Anson Funds Management sold out of Spero Therapeutics (SPRO) in Q2 2026, closing a stake of 421,956 shares — an estimated $987K sold.

Anson Funds Management first reported a position in SPRO in Q3 2022 and held it in 15 quarters. The position peaked at $6.45M in Q1 2024. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Anson Funds Management reported no remaining Spero Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Anson Funds Management sold 421,956 Spero Therapeutics shares in Q2 2026, an estimated $987K.
  • Anson Funds Management first reported a position in Spero Therapeutics in Q3 2022 and held it in 15 quarters.
  • Anson Funds Management's Spero Therapeutics position peaked at $6.45M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Anson Funds Management's 13F filing for Q2 2026, filed 13 Aug 2026.